220 related articles for article (PubMed ID: 28836002)
1. Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
Pitarokoili K; Yoon MS; Kröger I; Reinacher-Schick A; Gold R; Schneider-Gold C
J Neurol; 2017 Sep; 264(9):2010-2020. PubMed ID: 28836002
[TBL] [Abstract][Full Text] [Related]
2. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP.
Press R; Askmark H; Svenningsson A; Andersen O; Axelson HW; Strömberg U; Wahlin A; Isaksson C; Johansson JE; Hägglund H
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):618-24. PubMed ID: 24262917
[TBL] [Abstract][Full Text] [Related]
3. Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years.
Hiew FL; Ong JJ; Viswanathan S; Puvanarajah S
J Clin Neurosci; 2018 Apr; 50():203-207. PubMed ID: 29398193
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
[TBL] [Abstract][Full Text] [Related]
5. Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy.
Kuwabara S; Isose S; Mori M; Mitsuma S; Sawai S; Beppu M; Sekiguchi Y; Misawa S
J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1054-9. PubMed ID: 25424435
[TBL] [Abstract][Full Text] [Related]
6. Report of a fulminant anti-pan-neurofascin-associated neuropathy responsive to rituximab and bortezomib.
Fels M; Fisse AL; Schwake C; Motte J; Athanasopoulos D; Grüter T; Spenner M; Breuer T; Starz K; Heinrich D; Grond M; Keyvani K; Appeltshauser L; Doppler K; Sommer C; Ayzenberg I; Schneider-Gold C; Gold R; Pitarokoili K; Labedi A
J Peripher Nerv Syst; 2021 Dec; 26(4):475-480. PubMed ID: 34486194
[TBL] [Abstract][Full Text] [Related]
7. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.
Brannagan TH; Pradhan A; Heiman-Patterson T; Winkelman AC; Styler MJ; Topolsky DL; Crilley PA; Schwartzman RJ; Brodsky I; Gladstone DE
Neurology; 2002 Jun; 58(12):1856-8. PubMed ID: 12084892
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases.
Roux T; Debs R; Maisonobe T; Lenglet T; Delorme C; Louapre C; Leblond V; Viala K
J Peripher Nerv Syst; 2018 Dec; 23(4):235-240. PubMed ID: 30203907
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy.
Muley SA; Jacobsen B; Parry G; Usman U; Ortega E; Walk D; Allen J; Pasnoor M; Varon M; Dimachkie MM
Muscle Nerve; 2020 May; 61(5):575-579. PubMed ID: 31922613
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy.
Kaplan A; Brannagan TH
Muscle Nerve; 2017 Apr; 55(4):476-482. PubMed ID: 27463215
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
12. Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study.
Echaniz-Laguna A; de Séze J; Chanson JB
J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):699-705. PubMed ID: 22577230
[TBL] [Abstract][Full Text] [Related]
13. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.
Leitch MM; Sherman WH; Brannagan TH
Muscle Nerve; 2013 Feb; 47(2):292-6. PubMed ID: 23168526
[TBL] [Abstract][Full Text] [Related]
14. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
Chan YC; Allen DC; Fialho D; Mills KR; Hughes RA
J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):114-6. PubMed ID: 16361609
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide.
Jasmin R; Sockalingam S; Shahrizaila N; Cheah TE; Zain AA; Goh KJ
Lupus; 2012 Sep; 21(10):1119-23. PubMed ID: 22433918
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy.
Fatehi F; Okhovat AA; Panahi A; Ziaaddini B; Rajabally YA; Nafissi S
J Peripher Nerv Syst; 2021 Dec; 26(4):469-474. PubMed ID: 34469032
[TBL] [Abstract][Full Text] [Related]
17. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome.
Vina ER; Fang AJ; Wallace DJ; Weisman MH
Semin Arthritis Rheum; 2005 Dec; 35(3):175-84. PubMed ID: 16325658
[TBL] [Abstract][Full Text] [Related]
18. CIDP variants in diabetes: measuring treatment response with a small nerve fiber test.
Névoret ML; Vinik AI
J Diabetes Complications; 2015 Mar; 29(2):313-7. PubMed ID: 25466645
[TBL] [Abstract][Full Text] [Related]
19. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
Tracy JA; Dyck PJ
Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
[TBL] [Abstract][Full Text] [Related]
20. Does the chronic inflammatory demyelinating polyradiculoneuropathy due to secondary cause differ from primary?
Wadwekar V; Kalita J; Misra UK
Neurol India; 2011; 59(5):664-8. PubMed ID: 22019647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
